W. L. Gore and Associates

PhysioLogic Devices, Inc. is a California-based company established in 2013 that specializes in developing advanced implantable products aimed at transforming the treatment of insulin-requiring diabetes. The company focuses on creating an innovative implantable insulin pump that works in conjunction with a glucose sensor to automate glucose control. This technology delivers insulin directly to the intraperitoneal space for uptake by the liver, effectively normalizing glucose physiology. By providing a solution that allows for automatic regulation of insulin delivery, PhysioLogic Devices aims to offer patients with Type 1 diabetes a more liberated lifestyle, free from the challenges of traditional insulin therapy.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Quellan, Inc. designs, develops, and markets analog signal processing and radio frequency noise cancellation integrated circuits (IC) for application in automotive, computing, data center, storage, consumer electronics, and wireless markets. The company’s products include noise cancellers that sense unwanted noise and then apply an opposite signal to the receive path; system developer kits for mobile television applications and GPS applications; quad lane extenders ICs, which deliver analog signal integrity to data center equipment and interconnects; single lane extenders ICs; evaluation boards and kits; cable modules and active cables; and cable module kits. Its products are used in various data center applications, such as active cable, linecard, and backplane; and wireless applications, including global positioning systems and mobile television. The company was founded in 2001 and is headquartered in Santa Clara, California. As of August 6, 2009, Quellan, Inc. operates as a subsidiary of Intersil Corp.